Aster Springs Nashville
Aster Springs' Nashville Residential Facility

BRENTWOOD, Tenn., August 1, 2023 (Newswire.com) - Odyssey Behavioral Healthcare, a leading provider of eating disorder, mental health, and addiction treatment services, proudly announces the opening of the newest Aster Springs residential eating disorder treatment facility, licensed by the TN Department of Mental Health and Substance Abuse Services, in Nashville, Tennessee. Located minutes from downtown Music City, the latest addition to the Aster Springs residential treatment family underscores Odyssey's continued commitment to growth to address unmet demand. Aster Springs provides residential and outpatient treatment services in Indiana, Kentucky, Ohio, Tennessee, and Virginia and is their second location in Nashville, along with their Aster Springs Outpatient - Nashville clinic.

According to recent reports from the National Association of Anorexia Nervosa and Associated Disorders (ANAD):

• 28.8 million Americans will have an eating disorder in their lifetime.
• 10,200 deaths each year are the direct result of an eating disorder.
• Eating disorders are among the deadliest mental illnesses, second only to opioid overdoses.

"The need for eating disorder treatment at all levels of care continues to grow nationally for individuals with these complex conditions," said Richard Clark, CEO of Odyssey Behavioral Healthcare. "Odyssey is addressing Tennessee's underserved demand by opening additional residential services in Nashville. This new facility also strengthens Odyssey's growing national network of eating disorder residential and outpatient treatment services that provide quality care for those in need." 

Aster Springs is known for their whole-person approach to treatment, low client-to-clinician ratio, and unique, home-like settings. The Aster Springs residential treatment facility in Nashville cares for adult women with an eating disorder through a residential treatment program (RTC) and a partial hospitalization program (PHP). As a transformed songwriter's retreat, the facility's peaceful surroundings offer an idyllic environment and a small community for healing. 

"Aster Springs is recognized as a leading treatment program with residential and outpatient programs in five states," said Chrissy Hall, LCSW, Group CEO of Aster Springs. "Our clinical and support teams are some of the best in the industry. I'm proud to expand our proven combination of compassionate care and evidence-based approaches to more individuals in need with the addition of our newest Nashville, Tennessee location."

To learn more about our new Nashville treatment location, visit the Aster Springs website.

——————————-

About Odyssey Behavioral Healthcare

Odyssey, formed in 2015, has a diverse clinical network of services treating adults and adolescents for eating disorders, psychiatric disorders, dual diagnosis, and other addictive disorders. Odyssey provides a continuum of care within our Psychiatric Network and Eating Disorder Network, including inpatient, intensive residential, partial hospitalization, outpatient services, detoxification, and transitional living at over 35 locations and affiliated Odyssey Outpatient Network clinics in nine states with over 600 beds.

NEW YORK and RALEIGH, N.C., August 1, 2023 (Newswire.com) - Carebox, a leading provider of clinical trial matching solutions, and the Lung Cancer Research Foundation (LCRF), a leading nonprofit organization focused on research to extend survival and improve quality of life for people with lung cancer, today announced the launch of a Carebox Connect experience optimized for lung cancer patients. 

From the clinical trials page of the LCRF website, lung cancer patients, their caregivers and healthcare professionals can visit the Carebox Connect web application for an easy and effective way to search for and match to potentially relevant trials. By making this search resource available on its website, LCRF is connecting patients to research and enabling them to make the best treatment decisions for themselves.  

Visitors to the web application can complete a 10-question questionnaire about the patient's lung cancer condition and then instantly see which of over 1,000 actively recruiting clinical trials with treatment options are potentially relevant for them. They can then get connected to a trial research site for next steps. 

The Carebox Connect trial database is synchronized daily with the ClinicalTrials.gov clinical trial data maintained by the National Library of Medicine (NLM) at the National Institutes of Health (NIH). Applying its human-supervised AI, Carebox converts the unstructured text in ClinicalTrials.gov that describes eligibility criteria for enrollment into a searchable index of clinical criteria for matching with patient characteristics.

"Carebox Connect enables us to both advance research and make clinical trial treatment options much more accessible to the lung cancer patient community." 
-Aubrey Rhodes, Executive Director of LCRF

For more advanced users, full search and filtering capabilities are available. Filters can be saved for future use. Furthermore, based on those saved filters, users can subscribe to receive Carebox Connect notifications in their email inbox whenever new trials open (or new sites open) in a defined distance radius from where they are located. 

"LCRF is on a mission to improve lung cancer outcomes by funding research for prevention, diagnosis, treatment and cure. Patient participation in clinical trials is a critical component on the road to our vision of a world free of lung cancer," explains Aubrey Rhodes, Executive Director of LCRF, adding that "Carebox Connect enables us to both advance research and make clinical trial treatment options much more accessible to the lung cancer patient community."  

"The Carebox Connect Network has a common technology foundation and a unified end-user application," notes Assaf Levi, Carebox VP of R&D. "However, we can create customized experiences for each specific condition so that lung cancer patients arriving from LCRF are directed to the relevant questionnaire and trials for them. Knowing that we are touching the lives of so many patients and can help support efforts of organizations like LCRF in advancing such important research, is core to what makes working at Carebox special for the entire engineering team."

About the Lung Cancer Research Foundation 

The Lung Cancer Research Foundation® (LCRF) is the leading nonprofit organization focused on funding innovative, high-reward research with the potential to extend survival and improve quality of life for people with lung cancer. LCRF's mission is to improve lung cancer outcomes by funding research for the prevention, diagnosis, treatment, and cure of lung cancer. To date, LCRF has funded 409 research grants, totaling nearly $42 million, the highest amount provided by a nonprofit organization dedicated to funding lung cancer research. For more information, visit LCRF.org. 

About Carebox 

Carebox connects patients and physicians seeking treatment options with clinical trials. For patients and families, access to information about the newest and most advanced treatment options is obscured and frustrating to find. For pharma companies, clinical trial recruitment is the primary bottleneck in the $100B+ drug development market now being reshaped by precision medicine treatment specificity, new trial models, diversity requirements, and digital health consumer expectations. Carebox is at the forefront of addressing these challenges for patients and their families, as well as for the ecosystem of companies involved in sponsoring, running, and recruiting for clinical trials.  

Learn more about Carebox at careboxhealth.com. 

About Carebox Connect 

The Carebox Connect cloud platform digitizes Carebox's two decades of experience in navigating over one million patients seeking clinical trial options. It enables trial sponsors of all sizes to educate, engage, navigate, match, qualify, refer, and enroll patients in their clinical trials. Pharma trial sponsors, hospital research centers, and patient advocacy groups use Carebox Connect to present their clinical trial portfolios to the public, optimize trial recruitment, and enhance participant diversity in support of ongoing clinical research. 

About The Carebox Connect Network 

In addition to customer-branded Carebox Connect solutions for trials sponsors and sites, the Carebox Connect Network brings the power of the platform to patients, families, and caregivers via a rapidly growing network of dozens of patient advocacy groups and physician associations reaching tens of thousands of patients. Carebox runs co-branded and branded web applications and/or clinical trial navigation services on behalf of its Carebox Connect Network partners.  

StatSeal Advanced Plus Disc for Femoral Groin Closure

SARASOTA, Fla., August 1, 2023 (Newswire.com) - The acclaimed Essex Cardiothoracic Centre, part of Mid and South Essex NHS Foundation Trust, was recognized with an award following their cutting-edge clinical study that evaluated a novel groin closure method to allow rapid same-day discharge following atrial fibrillation (AF) ablation procedures to treat patients with irregular heartbeats.

The study evaluated using the StatSeal® Advanced Plus Disc (Biolife, LLC) for femoral vein groin closure of AF ablation patients who remained on their anticoagulation medications. The previous closure method used was physician-placed sutures. During the study, 50 AF ablations were performed, and StatSeal Advanced Plus Disc was applied to the groin closure site by technicians, not the physicians, with only 5 to 10 minutes of manual pressure. The median recovery time for the StatSeal group was just 2 hours, compared to 4 hours with the suture closure method. The median discharge time for the StatSeal group was only 2.5 hours, compared to 5 hours with the suture closure method. StatSeal use resulted in a more than 50% decrease in recovery time, with no rise in complications, allowing patients to safely mobilize and get home earlier compared to the suture closure method. The study concluded that StatSeal use will likely lead to increased same-day discharge and fewer overnight stays following AF ablations.

As a result of this study, which demonstrates the efficacy of StatSeal use for groin closure, the Essex Cardiothoracic Centre has been recognized globally as a Centre of Excellence for Atrial Fibrillation by the Atrial Fibrillation Association. The study was published in the 2023 AF Healthcare Pioneer Report, which can be found online at: https://api.heartrhythmalliance.org/files/download/621e9388e8269ecaa50c07a133797450

Lead investigator Rhoel Peralta, Cath Lab Associate Practitioner at MSE Hospitals, commented, "Our efforts and success prove that we can all play our part for patients and make a difference, and this acknowledgment reinforces our commitment to providing exceptional care to our patients. We are thrilled to be recognized as a Centre of Excellence and AF Healthcare Pioneers. I am part of a much larger team where everyone came together and worked tirelessly."

Biolife, LLC

Biolife, LLC is a privately-owned medical device company headquartered in Sarasota, Florida, that manufactures innovative healthcare and first aid solutions that stop bleeding fast and improve patient outcomes. All Biolife products are comprised of a powder with two main ingredients: potassium ferrate and a hydrophilic polymer. The products work independently of the clotting cascade to seal the wound or procedural site, while accelerating hemostasis. The low pH seal created by the powder helps reduce risk of infection and helps improve recovery time. StatSeal® products for the healthcare industry are available in powder and disc (compressed powder) form to suit a wide variety of clinical applications. For more information, visit: https://www.biolife.com/

Propelus
logo

JACKSONVILLE BEACH, Fla., August 1, 2023 (Newswire.com) - The parent company behind leading workforce compliance management and continuing education products CE Broker, EverCheck, and Immuware, today unveiled a new corporate brand — Propelus — to unify the group's vision to "power professional progress'' through dynamic compliance for our nation's workforce. 

The new brand identity reflects significant growth transformation at the company, bringing together the Propelus product portfolio with a renewed sense of purpose to modernize how professionals, their employers, regulators, agencies, and associations work better together. The new "propeller" logo demonstrates the full lifecycle of professional progress focused on innovation, relationships, and forward momentum alongside the new name.   

Propelus (pronounced propel·us) embodies the company's dynamic market-leading technology, vital data, and dedication to streamlining and simplifying compliance for total professional management. At the heart of the rebranding initiative are the millions of healthcare and other dedicated workers serving as the inspiration behind the group's shared mission. 

"Introducing Propelus marks a significant milestone along our 20-year mission to empower professional progress throughout the career journey and, ultimately, help safeguard our communities," said Julie Walker, CEO of Propelus. "We are focused on ensuring that Propelus is synonymous with our values-driven approach to simplifying workforce compliance for better outcomes - together." 

The arrival of Propelus comes as companies in the healthcare, education, and government technology industries consolidate and require digital transformation to standardize, automate, and simplify their processes. Additionally, as technology advances to streamline, simplify, and elevate how organizations operate, Propelus creates much-needed connections between stakeholders, privileged partner relationships, and professionals with access to the most reliable, trusted, and automated data in the market.

Launching a unified website accompanies the transition to the new Propelus name. Propelus is trusted by more than 5 million professionals, employers, regulators, and partners through its suite of workforce management and compliance technology solutions.  

About Propelus 

Propelus is modernizing how professionals, their employers, regulators, and associations work better together. For over 20 years, Propelus solutions — CE Broker, EverCheck, and Immuware — have propelled the progress of millions of dedicated professionals in their career journey. Our market-leading workforce compliance management technology, full-lifecycle continuing education software, and vital data simplify total professional management for a happier workforce, better operations, and safer communities.

We power professionals. 

Learn more at www.propelus.com.